Cargando…

The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs

AIMS: To describe the effects of the K(Ca)2 channel inhibitor AP30663 in pigs regarding tolerability, cardiac electrophysiology, pharmacokinetics, atrial functional selectivity, effectiveness in cardioversion of tachy-pacing induced vernakalant-resistant atrial fibrillation (AF), and prevention of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Diness, Jonas Goldin, Kirchhoff, Jeppe Egedal, Speerschneider, Tobias, Abildgaard, Lea, Edvardsson, Nils, Sørensen, Ulrik S., Grunnet, Morten, Bentzen, Bo Hjorth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059611/
https://www.ncbi.nlm.nih.gov/pubmed/32180722
http://dx.doi.org/10.3389/fphar.2020.00159
_version_ 1783504084102283264
author Diness, Jonas Goldin
Kirchhoff, Jeppe Egedal
Speerschneider, Tobias
Abildgaard, Lea
Edvardsson, Nils
Sørensen, Ulrik S.
Grunnet, Morten
Bentzen, Bo Hjorth
author_facet Diness, Jonas Goldin
Kirchhoff, Jeppe Egedal
Speerschneider, Tobias
Abildgaard, Lea
Edvardsson, Nils
Sørensen, Ulrik S.
Grunnet, Morten
Bentzen, Bo Hjorth
author_sort Diness, Jonas Goldin
collection PubMed
description AIMS: To describe the effects of the K(Ca)2 channel inhibitor AP30663 in pigs regarding tolerability, cardiac electrophysiology, pharmacokinetics, atrial functional selectivity, effectiveness in cardioversion of tachy-pacing induced vernakalant-resistant atrial fibrillation (AF), and prevention of reinduction of AF. METHODS AND RESULTS: Six healthy pigs with implanted pacemakers and equipped with a Holter monitor were used to compare the effects of increasing doses (0, 5, 10, 15, 20, and 25 mg/kg) of AP30663 on the right atrial effective refractory period (AERP) and on various ECG parameters, including the QT interval. Ten pigs with implanted neurostimulators were long-term atrially tachypaced (A-TP) until sustained vernakalant-resistant AF was present. 20 mg/kg AP30663 was tested to discover if it could successfully convert vernakalant-resistant AF to sinus rhythm (SR) and protect against reinduction of AF. Seven anesthetized pigs were used for pharmacokinetic experiments. Two pigs received an infusion of 20 mg/kg AP30663 over 60 min while five pigs received 5 mg/kg AP30663 over 30 min. Blood samples were collected before, during, and after infusion on AP30663. AP30663 was well-tolerated and prominently increased the AERP in pigs with little effect on ventricular repolarization. Furthermore, it converted A-TP induced AF that had become unresponsive to vernakalant, and it prevented reinduction of AF in pigs. Both a >30 ms increase of the AERP and conversion of AF occurred in different pigs at a free plasma concentration level of around 1.0–1.4 µM of AP30663, which was achieved at a dose level of 5 mg/kg. CONCLUSION: AP30663 has shown properties in animals that would be of clinical interest in man.
format Online
Article
Text
id pubmed-7059611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70596112020-03-16 The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs Diness, Jonas Goldin Kirchhoff, Jeppe Egedal Speerschneider, Tobias Abildgaard, Lea Edvardsson, Nils Sørensen, Ulrik S. Grunnet, Morten Bentzen, Bo Hjorth Front Pharmacol Pharmacology AIMS: To describe the effects of the K(Ca)2 channel inhibitor AP30663 in pigs regarding tolerability, cardiac electrophysiology, pharmacokinetics, atrial functional selectivity, effectiveness in cardioversion of tachy-pacing induced vernakalant-resistant atrial fibrillation (AF), and prevention of reinduction of AF. METHODS AND RESULTS: Six healthy pigs with implanted pacemakers and equipped with a Holter monitor were used to compare the effects of increasing doses (0, 5, 10, 15, 20, and 25 mg/kg) of AP30663 on the right atrial effective refractory period (AERP) and on various ECG parameters, including the QT interval. Ten pigs with implanted neurostimulators were long-term atrially tachypaced (A-TP) until sustained vernakalant-resistant AF was present. 20 mg/kg AP30663 was tested to discover if it could successfully convert vernakalant-resistant AF to sinus rhythm (SR) and protect against reinduction of AF. Seven anesthetized pigs were used for pharmacokinetic experiments. Two pigs received an infusion of 20 mg/kg AP30663 over 60 min while five pigs received 5 mg/kg AP30663 over 30 min. Blood samples were collected before, during, and after infusion on AP30663. AP30663 was well-tolerated and prominently increased the AERP in pigs with little effect on ventricular repolarization. Furthermore, it converted A-TP induced AF that had become unresponsive to vernakalant, and it prevented reinduction of AF in pigs. Both a >30 ms increase of the AERP and conversion of AF occurred in different pigs at a free plasma concentration level of around 1.0–1.4 µM of AP30663, which was achieved at a dose level of 5 mg/kg. CONCLUSION: AP30663 has shown properties in animals that would be of clinical interest in man. Frontiers Media S.A. 2020-02-28 /pmc/articles/PMC7059611/ /pubmed/32180722 http://dx.doi.org/10.3389/fphar.2020.00159 Text en Copyright © 2020 Diness, Kirchhoff, Speerschneider, Abildgaard, Edvardsson, Sørensen, Grunnet and Bentzen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Diness, Jonas Goldin
Kirchhoff, Jeppe Egedal
Speerschneider, Tobias
Abildgaard, Lea
Edvardsson, Nils
Sørensen, Ulrik S.
Grunnet, Morten
Bentzen, Bo Hjorth
The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
title The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
title_full The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
title_fullStr The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
title_full_unstemmed The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
title_short The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
title_sort k(ca)2 channel inhibitor ap30663 selectively increases atrial refractoriness, converts vernakalant-resistant atrial fibrillation and prevents its reinduction in conscious pigs
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059611/
https://www.ncbi.nlm.nih.gov/pubmed/32180722
http://dx.doi.org/10.3389/fphar.2020.00159
work_keys_str_mv AT dinessjonasgoldin thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT kirchhoffjeppeegedal thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT speerschneidertobias thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT abildgaardlea thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT edvardssonnils thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT sørensenulriks thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT grunnetmorten thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT bentzenbohjorth thekca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT dinessjonasgoldin kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT kirchhoffjeppeegedal kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT speerschneidertobias kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT abildgaardlea kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT edvardssonnils kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT sørensenulriks kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT grunnetmorten kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs
AT bentzenbohjorth kca2channelinhibitorap30663selectivelyincreasesatrialrefractorinessconvertsvernakalantresistantatrialfibrillationandpreventsitsreinductioninconsciouspigs